FDA declines approval for Novo Nordisk’s diabetic medicine
Novo Nordisk, has been denied approval for its type 1 diabetic medicine by the USFDA, according to the Danish drugmaker.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Novo Nordisk, has been denied approval for its type 1 diabetic medicine by the USFDA, according to the Danish drugmaker.
OraSure Technologies’ hepatitis C virus self-test has been prequalified by the World Health Organization in a global bid to eliminate the disease.
Pharmacy benefit managers, who handle about 95% of US prescriptions, are inflating drug costs and squeezing independent pharmacies, according to a report.
Intensive diet and lifestyle changes may forestall a cognitive decline in Alzheimer’s disease and make progress for patients during early stages, a study.
Children are vulnerable to temperature changes as their thermoregulation mechanisms are still immature, a study reveals.
June was the hottest month since the records began and the thirteenth month in a row to set a monthly temperature record, according.
Eli Lilly and Company will acquire biopharmaceutical firm, Morphic Holding Inc., for $3.2 billion in cash, giving it access to a molecule inhibitor.
Urgent steps are needed to study the dynamics of the circulating viral strains about its vector, hosts and environment for developing effective preventive.
HQ Team July 5, 2024: The Europen Union has approved AstraZeneca’s Tagrisso along with chemotherapy treatment for lung cancer patients after trials showed.
Swiss drugmaker, Roche, halted a lung cancer trial after it failed to meet the goal of progression-free survival compared to an existing treatment.